MKC9989 is primarily utilized in the pharmaceutical industry for its potential therapeutic properties. It is being investigated for its efficacy in treating specific types of cancers, particularly those resistant to conventional therapies. The compound has shown promise in preclinical studies by targeting unique pathways involved in tumor growth and metastasis, making it a candidate for further clinical trials. Additionally, it is being explored for its potential use in combination therapies to enhance the effectiveness of existing treatments. Researchers are also examining its role in modulating immune responses, which could lead to applications in immunotherapy. Its development is closely monitored for safety and efficacy to ensure it meets regulatory standards for future medical use.